Hims
FDA Scrutinizes Telehealth Firms Like Hims for GLP-1 Drug Advertising Practices
FDA; Hims; telehealth; GLP-1; advertising; weight-loss drugs; compound drugs; Super Bowl ad; misleading claims
Hims eyes growth in its weight loss business, despite end of semaglutide shortage
semaglutide, weight loss business, United States Food and Drug Administration, Growth, Hims
Hims Secures Drug Supply for Thriving Weight Loss Business
Hims, weight loss drugs, compounded GLP-1, drug supply, booming business, revenue growth, subscriber base